Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00395382
Other study ID # HREC 06099C
Secondary ID
Status Completed
Phase Phase 4
First received November 1, 2006
Last updated February 8, 2010
Start date January 2007
Est. completion date September 2009

Study information

Verified date February 2010
Source Monash University
Contact n/a
Is FDA regulated No
Health authority Australia: Human Research Ethics CommitteeAustralia: Department of Health and Ageing Therapeutic Goods Administration
Study type Interventional

Clinical Trial Summary

Cardiovascular disease (CVD) is the commonest cause of mortality in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Reasons for the greater incidence of CVD in this group include traditional CVD risk factors of hypertension, dyslipidemia and diabetes but more importantly also include non-traditional risk factors such as calcium and phosphate imbalance. The latter is thought most likely to contribute to vascular calcification, especially for those on dialysis, and this in turn leads to arterial stiffness and left ventricular hypertrophy, the two commonest cardiovascular complications. Arterial stiffness and calcification have been found to be independent predictors of all-cause and cardiovascular mortality in CKD. Few studies, though, have looked at both structural and functional changes associated with calcification and there have been very few interventional studies addressing this issue.

Control of calcium and phosphate levels in CKD can occur with the use of medications that reduce elevated serum phosphate (phosphate binders, mostly calcium-based) and those to treat hyperparathyroidism (vitamin D and more recently calcium sensing receptor agonists called calcimimetics). These pharmacological managements addressing calcium and phosphate imbalance reduce vascular calcification and CVD. Bisphosphonate therapy may also have a role in reduction of calcification.

Low bone mineral density (BMD) is common in CKD patients and predicts increased fracture risk similar to the general population. Bisphosphonate therapy improves BMD and lowers the fracture risk. Bisphosphonates may also have a role in secondary hyperparathyroidism to reduce hypercalcemia and allow for more aggressive calcitriol treatment. Recent studies have addressed the possibility of bisphosphonates reducing the progression of vascular calcification in CKD and revealed that the extent of calcification may be suppressed in association with a reduction in chronic inflammatory responses.

The investigators aim to perform a prospective, randomised study assessing the impact of alendronate on cardiovascular and bone mineral parameters. This will be a single-centre study involving subjects with CKD Stage 3 (those patients with GFR between 30 and 59ml/min). Arterial stiffness (by pulse wave analysis and pulse wave velocity) and vascular calcification (using CT scans through superficial femoral artery) will be followed as well as serum markers of calcium, phosphate and PTH. Differences in these end-points will be compared between participants taking alendronate and those not. The study will be conducted over a 12 month period and the investigators aim to recruit about 50 patients (25 on alendronate and 25 control).


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 2009
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Subjects with CKD Stage 3 (GFR between 30 and 59ml/min)

- Subjects must be 18 years of age or older

- Willingness to provide written informed consent

Exclusion Criteria:

- Subjects unable to give informed consent or whom have an expected life-span of less than 3 months

- Subjects undertaking renal replacement therapy (dialysis or transplantation)

- Subjects already taking bisphosphonates

- Subjects with recent fracture (within the last 3 months)

- Subjects scheduled to have a kidney transplant from a known living donor

- Subjects with active gastro-oesophageal reflux disease or peptic ulcer disease

- Subjects who are pregnant or planning on becoming pregnant in the next 18 months

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Drug:
Alendronate
70mg weekly orally
Placebo
weekly orally

Locations

Country Name City State
Australia Department of Nephrology, Monash Medical Centre Clayton Victoria

Sponsors (1)

Lead Sponsor Collaborator
Monash University

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in degree of arterial stiffness measured by pulse wave velocity 18 months No
Primary Changes in vascular calcification on CT scans of superficial femoral artery and aorta 18 months No
Secondary Changes in bone mineral density 18 months No
Secondary Changes in serum calcium and phosphate levels 18 months No
Secondary Cardiovascular events including myocardial ischaemia, myocardial infarction, cardiac failure, stroke, PVD 18 months No
Secondary Incidence of fractures 18 months No
Secondary Symptoms and severity of side effects from alendronate 18 months Yes
Secondary Episodes of hypocalcemia (serum corrected calcium <2.10mmol/L) 18 months Yes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Not yet recruiting NCT02866656 - The Clinical Research of Low Intensity Continuous Ultrasonic on Lower Limb Arteriosclerosis Occlusion(ASO) Syndrome N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Active, not recruiting NCT00154180 - Kronos Early Estrogen Prevention Study (KEEPS) Phase 4
Recruiting NCT04343209 - Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
Not yet recruiting NCT06039748 - Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Recruiting NCT04142021 - Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
Recruiting NCT06008756 - MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes Phase 3
Completed NCT03253692 - Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Active, not recruiting NCT04624854 - Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) Phase 4
Active, not recruiting NCT02921230 - Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery N/A
Recruiting NCT01774058 - The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation Phase 2
Terminated NCT01462721 - The eSVS® Mesh Randomized Post-Market Study N/A
Completed NCT01455974 - The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients N/A
Completed NCT01221610 - BIOLUX P-I First in Man Study N/A
Active, not recruiting NCT00863967 - Early Detection of Arteriosclerosis N/A
Active, not recruiting NCT00174902 - The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress Phase 1/Phase 2
Completed NCT00050817 - Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Phase 3